<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00909987</url>
  </required_header>
  <id_info>
    <org_study_id>GEMCAD-0801</org_study_id>
    <nct_id>NCT00909987</nct_id>
  </id_info>
  <brief_title>Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum</brief_title>
  <official_title>Phase II, Multicenter, Open-label, Non-randomized Study of Neoadjuvant Chemotherapy With Selective Radiotherapy Use in Patients With Intermediate-Risk Cancer of the Rectum Defined by Magnetic Resonance Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol Multidisciplinario del Cancer Digestivo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Espanol Multidisciplinario del Cancer Digestivo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II, Multicenter, Open-label, Non-randomized Study of Neoadjuvant Chemotherapy&#xD;
      (CAPECITABINE-OXALIPLATIN + BEVACIZUMAB) with Selective Radiotherapy and Chemotherapy with&#xD;
      CAPECITABINE Use in Patients with Intermediate-Risk Cancer of the Rectum Defined by Magnetic&#xD;
      Resonance Imaging.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      XELOX / Bevacizumab will be administrated for 3 cycles over a 9 week period. XELOX without&#xD;
      Bevacizumab will be administrated for an additional cycle over a 4 week period. Patients will&#xD;
      undergo re-staging within 3 weeks of their 4th cycle of XELOX. This will include MRI of the&#xD;
      pelvis. If the reassessment reveals that there has been no disease progression compared to&#xD;
      the pre-treatment evaluation and the patient remains a candidate for an R0 resection, the&#xD;
      patient will proceed to definitive rectal cancer surgery within 4 weeks from the last&#xD;
      chemotherapy dose. If the surgical oncologist's reassessment reveals that the patient is not&#xD;
      a candidate for an R0 resection, the patient will proceed to standard pre-operative radiation&#xD;
      with synchronous Capecitabine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of XELOX/BVZ neoadjuvant therapy with selective radiotherapy use in patients with locally advanced tumors of the rectum, measured in terms of the proportion of responders (PCR + CCR), according to RECIST criteria</measure>
    <time_frame>Until the end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study treatment,which selectively omits neoadjuvant irradiation,can achieve a R0= 90%</measure>
    <time_frame>At least 3 years for local recurrence and systemic recurrence</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of local and systemic recurrence</measure>
    <time_frame>At least 3 years for local recurrence and systemic recurrence</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of treatment</measure>
    <time_frame>At least 3 years for local recurrence and systemic recurrence</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of surgical complications during postoperative</measure>
    <time_frame>At least 3 years for local recurrence and systemic recurrence</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of gene expression before neoadjuvant treatment</measure>
    <time_frame>At least 3 years for local recurrence and systemic recurrence</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Phatologic Response (pCR)</measure>
    <time_frame>2012</time_frame>
    <description>Complete pathologic response (pCR)estimated according to the number of subjects that showed yPT0N0 divided by the total number of subjects.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Rectum Cancer</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadyuvant chemotherapy with XELOX: Xeloda 1000mg/m2/12h dayly, day one in the afternoon until day 15 in the morning; plus oxaliplatin 130mg/m2 (day 1); and Bevacizumab 7.5 mg/kg (day 1)during 3 cycles (each cycle of 3 weeks).&#xD;
Followed by a selective use of chemoradiotherapy with radiotherapy (50.4Gy, 28 sesions of 1.8Gy during 5 weeks) plus Xeloda 825mg/m2/12h dayly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>PO 1000 mg/m2 bid during day 1 to 15 for 3 cycles (every cycle has 3 weeks)</description>
    <arm_group_label>Single arm</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>IV 130 mg/m2 during day 1 for 3 cycles (every cycle has 3 weeks)</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>IV 7.5 mg/Kg during 30 minutes day 1 during 4 cycles (every cycle has 3 weeks)</description>
    <arm_group_label>Single arm</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Total dose 50.4 Gy administered during 28 days (1.8 Gy/day in 5 weeks).</description>
    <arm_group_label>Single arm</arm_group_label>
    <other_name>Neoadjuvant Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine during all Radiotherapy period</intervention_name>
    <description>825 mg/m2 bid</description>
    <arm_group_label>Single arm</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total Mesorectal Excision (TME)</intervention_name>
    <description>4 weeks from the last chemotherapy dose. In those patients who receive radiation TME wil be performed six weeks after</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient ≥18 years&#xD;
&#xD;
          -  Tumor biopsy with histopathologic confirmation of rectal adenocarcinoma as primary&#xD;
             histology&#xD;
&#xD;
          -  Patient with measurable disease at the baseline visit&#xD;
&#xD;
          -  T3 tumor that meets all the following criteria in high-resolution magnetic resonance&#xD;
             imaging (MRI) (3-mm slices) of the pelvis: distal border of tumor more than 5cm form&#xD;
             the external edge of the anus and below the sacral promontory (located in the anatomy&#xD;
             rectum).&#xD;
&#xD;
          -  Candidate for complete surgical resection (R0) with sphincter preservation surgery,&#xD;
             prior to the administration of any therapy&#xD;
&#xD;
          -  Candidate for systemic therapy with XELOX/BVZ&#xD;
&#xD;
          -  ECOG: 0-2&#xD;
&#xD;
          -  ANC≥1.5 cells/mm3, Hb&gt;8.0 g/dL, platelets&gt;150,000/mm3 in 2 previous weeks&#xD;
&#xD;
          -  Patient who signed the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stage T4.&#xD;
&#xD;
          -  Distant metastases&#xD;
&#xD;
          -  Tumor with an intraperitoneal distal border&#xD;
&#xD;
          -  Tumor presenting initially in a low location and judged, prior to any treatment, to&#xD;
             require abdominoperineal resection&#xD;
&#xD;
          -  Previous chemotherapy for colorectal cancer or incomplete recovery from oncologic&#xD;
             surgery or other previous major surgery that, in the opinion of the investigator,&#xD;
             precludes the use of a combined modality therapy&#xD;
&#xD;
          -  Serum creatinine &lt;1.5 ULN&#xD;
&#xD;
          -  Patient who has received previous pelvic radiotherapy&#xD;
&#xD;
          -  Patient with an uncontrolled infection&#xD;
&#xD;
          -  Presence of a high degree of obstruction (intestinal lumen ≤ 1 cm), unless the patient&#xD;
             has undergone protective surgical bypass or an endoscopic stent procedure&#xD;
&#xD;
          -  Pt with a history of an arterial thromboembolic event during the previous year.This&#xD;
             includes angina (stable or unstable),myocardial infarction (MI),cerebrovascular&#xD;
             accident (CVA),or other relevant history in the opinion of the investigator.Note: A&#xD;
             patient with a history of thrombotic events, such as deep venous thrombosis, pulmonary&#xD;
             embolism, MI or ACV, within the 6 months preceding recruitment may be considered for&#xD;
             participation in the clinical trial if they are receiving stable doses of&#xD;
             anticoagulant therapy. Similarly, patients being anticoagulated for atrial&#xD;
             fibrillation or other conditions can participate if they are receiving a stable dosage&#xD;
             of anticoagulant therapy. Clinicians must consider the higher risk of therapy with BVZ&#xD;
             among patients with a history of thromboembolic disorders so the decision to allow the&#xD;
             patients to participate remains at the discretion of the physician&#xD;
&#xD;
          -  Previous treatment with another investigational antitumoral therapy in the 30 days&#xD;
             prior to beginning treatment&#xD;
&#xD;
          -  History of previous malignancy in the past 5 years, excepting basocellular or squamous&#xD;
             cell skin cancer, or properly treated cervix cancer in situ&#xD;
&#xD;
          -  Woman with a positive pregnancy test in urine or serum during recruitment, prior to&#xD;
             the administration of the study medication, or within 72 hours of beginning to take&#xD;
             the study medication, or a woman who is nursing&#xD;
&#xD;
          -  WOCBP who does not wish to use or cannot use an effective contraceptive method to&#xD;
             avoid pregnancy during the complete study period up to 4 weeks after ending the&#xD;
             study.Male subjects also must agree to use an effective method of contraception.Note:&#xD;
             WOCBP refers to any woman who has experienced menarche and has not undergone&#xD;
             successful surgical sterilization or is not postmenopausal (defined as amenorrhea≥12&#xD;
             consecutive months,or women with hormonal replacement therapy and documented serum&#xD;
             levels of follicle stimulating hormone).Even women who are using oral, implanted or&#xD;
             injectable contraceptive hormones, mechanical products such as an intrauterine device&#xD;
             or barrier methods to prevent pregnancy,or who practice abstinence or have a sterile&#xD;
             partner, must be assumed to be WOCBP&#xD;
&#xD;
          -  Patient with any other condition or concurrent medical or psychiatric disease who,in&#xD;
             opinion of the investigator, is not eligible to enter the study&#xD;
&#xD;
          -  Known hypersensitivity to any component of the study drug (XELOX/bevacizumab) or&#xD;
             radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Fernández Martos, Oncologist</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto Valenciano de Oncología (IVO)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carles Pericay, Oncologist</last_name>
    <role>Study Director</role>
    <affiliation>Complejo Sanitario Parc Taulí</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonieta Salud, Oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Arnau de Villanova (Lérida)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vicente Alonso, Oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Miguel Servet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>María José Safont, Oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruth Vera, Oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pilar Escudero, Oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario Lozano Blesa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joan Maurel, Oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic i provincial de Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorge Aparicio, Oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital La Fe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jaime Feliú, Oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mengual, Radiotherapy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Valenciano de Oncología (IVO)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moisés Miraflores, Radiotherapy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Arnau de Vilanova (Lérida)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martín Tejedor Gutierrez, Radiotherapy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Miguel Servet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Hernández Machancoses, Radiotherapy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando Arias de la Vega, Radiotherapy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Valencia, Radiotherapy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario Lozano Blesa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carles Conill, Radiotherapy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic i provincial de Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alejandro Tormo Micó, Radiotherapy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital La Fe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>María Elena Sánchez Santos, Radiotherapy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorge Campos, Surgeon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Valenciano de Oncología (IVO)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enrique Sierra Grañón, Surgeon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Arnau de Vilanova (Lérida)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrés Monzón, Surgeon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Miguel Servet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Vicente Roig, Surgeon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Suárez Alecha, Surgeon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eloy Tejero, Surgeon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario Lozano Blesa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Lazy, Surgeon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic i provincial de Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael Estevan, Surgeon</last_name>
    <role>Study Director</role>
    <affiliation>Hospital La Fe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Damián García Olmo, Surgeon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesús Santos, Radiologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto valenciano de Oncología (IVO)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Darnell, Radiologist</last_name>
    <role>Study Director</role>
    <affiliation>Complejo Sanitario Parc Taulí</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luís Sarriá, Radiologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Miguel Servet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vicente Martínez Sanjuán, Radiologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Jiménez, Radiologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Antonio Fernández Gómez, Radiologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario Lozano Blesa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Ramón Ayuso, Radiologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic i provincial de Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando Mas Estellés, Radiologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital La Fe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paula Alegría Hidalgo, Radiologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Caltrava, Pathologist</last_name>
    <role>Study Director</role>
    <affiliation>Instituto Valenciano de Oncología (IVO)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alex Casalots, Pathologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Sanitario de Parc Taulí</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xavier Matias-Guiu Guia, Pathologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Arnau de Vilanova (Lérida)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Hörndler, Pathologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Miguel Servet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Encarna Martínez, Pathologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>María Luisa Gómez Dorronsoro, Pathologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Ortego, Pathologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinico Universitario Lozano Blesa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>María José Artes, Pathologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital La Fe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marta Martín Richard, Oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel Gallén, Oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital del Mar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Gallego, Oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario de Elche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Sanitario Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Lérida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología (IVO)</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>March 23, 2009</study_first_submitted>
  <study_first_submitted_qc>May 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2009</study_first_posted>
  <last_update_submitted>October 10, 2013</last_update_submitted>
  <last_update_submitted_qc>October 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rectum</keyword>
  <keyword>intermediate risk cancer rectum</keyword>
  <keyword>neoadjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

